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Abstract
Background: The use and possible effects of factors known to improve outcomes in patients with
human immunodeficiency virus associated nephropathy (HIVAN), namely of angiotensin converting
enzyme inhibitors (ACE) and antiretroviral therapy, has not been reported for a national sample of
dialysis patients.
Methods: We conducted a historical cohort study of the United States Renal Data System
(USRDS) Dialysis Morbidity and Mortality Study (DMMS) Wave 2 to identify risk factors associated
with increased mortality in these patients. Data were available for 3374 patients who started
dialysis and were followed until March 2000. Cox Regression analysis was used to model adjusted
hazard ratios (AHR) with HIVAN as a cause of end stage renal disease (ESRD) and its impact on
mortality during the study period, adjusted for potential confounders.
Results: Of the 3374 patients who started dialysis, 36 (1.1%) had ESRD as a result of HIVAN. Only
22 (61%) of patients with HIVAN received antiretroviral agents, and only nine patients (25%)
received combination antiretroviral therapy, and only 14% received ACE inhibitors. Neither the
use of multiple antiretroviral drugs (AHR, 0.62, 95% CI, 0.10, 3.86, p = 0.60), or ACE inhibitors
were associated with a survival advantage. Patients with HIVAN had an increased risk of mortality
(adjusted hazard ratio, 4.74, 95% Confidence Interval, 3.12, 7.32, p < 0.01) compared to patients
with other causes of ESRD.
Conclusions:  Medications known to improve outcomes in HIV infected patients were
underutilized in patients with HIVAN. Adjusted for other factors, a primary diagnosis of HIVAN
was associated with increased mortality compared with other causes of ESRD.
Background
Previously limited to case series, [1–4] information on the
patient characteristics and course of human immunodefi-
ciency virus or acquired immunodeficiency syndrome
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associated nephropathy (HIVAN) after the onset of end
stage renal disease (ESRD) has been reported for the
national population of US ESRD patients. [5,6] Substan-
tial improvements in the survival of dialysis patients with
HIV infection have been noted after 1995,[6] and have
been attributed to treatment with highly active antiretro-
viral therapy (HAART). [7] Despite these encouraging
reports, the morbidity and mortality of these patients
remains high compared with age-matched patients with
ESRD from other causes. [6] Despite the improving infor-
mation on the pharmacokinetics of these drugs in dialysis
patients, a recent report suggested that only 58% of the 62
HIV-infected patients with ESRD were on antiretroviral
therapy. [8] Use of angiotensin converting enzyme inhib-
itors (ACE) in patients with HIVAN is associated with
delayed progression to ESRD. [9,10] Some other reports
have suggested that use of ACE in dialysis patients may
improve survival. [11] It is possible the use of ACE might
be particularly beneficial in HIV infected patients with
ESRD particularly those with HIV associated nephropathy
as heavy proteinuria often continues after the onset of
dialysis [12]. Alternatively, risk of hyperkalemia from ACE
in patients with HIVAN due to associated tubulointersti-
tial inflammation and renal tubular acidosis may increase
mortality. [13] Although a recent single-center report
found no benefit of ACE in dialysis patients with HIVAN
[14], it is not clear whether this represents national
experience.
Recent anecdotal reports of remission of HIVAN with use
of HAART are encouraging. However, the prevalence of
patients with HIVAN who develop ESRD may not
decrease, because of improvement in survival of these
patients, allowing them to live long enough to reach
ESRD. [15–17] Such patients may even be more difficult
to manage, since the onset of HIVAN could be delayed
until these patients develop resistance to the therapy.
Therefore, HIVAN is likely to continue as a major cause of
ESRD in young African-Americans. Better understanding
of factors associated with poor outcomes in patients with
HIVAN and ESRD would help in improving outcomes in
these patients. More detailed information on the meta-
bolic, cardiovascular and chronic kidney disease specific
characteristics of HIVAN patients on dialysis, as well as the
use and possible benefit of certain medications, especially
ACE and antiretroviral drugs in this population, would
supplement previous reports. Further, use of a national
database would allow the comparison of HIVAN patients
in a large at-risk population and allow comparison with
single center studies that may reflect practices that may
not be representative of the national as a whole. There-
fore, we analyzed data from the standard analysis files of
the 2000 United States Renal Data System (USRDS) Dial-
ysis Morbidity and Mortality (DMMS) Wave 2 database.
The primary objective of the study was to examine
whether patients with HIVAN who present to chronic
dialysis had important differences in clinical and labora-
tory parameters compared to patients with other causes of
ESRD and to assess factors associated with better survival
such as laboratory parameters and medication use.
Methods
A historical cohort study of the USRDS DMMS Wave 2 was
performed. Details on the inception, limitations, validity,
variables and questionnaires used in the study are availa-
ble online at the USRDS researcher's guide website, http:/
/www.usrds.org/research.htm. This database has been
used in many previous cross-sectional and longitudinal
studies including one by our own institution. [18]. Briefly,
DMMS WAVE 2 was a prospective cohort study of a ran-
dom sample of 20% of all U.S. hemodialysis patients and
virtually all peritoneal dialysis patients starting treatment
in 1996 and early 1997. Because patients who started dial-
ysis in 1997 comprised only a small proportion of the
study population, we limited analysis to patients who
started dialysis in 1996. Also, because outcomes such as
dates of death and follow-up had to be merged with this
study from other USRDS files, we did not consider it a true
prospective cohort study for the purposes of this analysis.
Characteristics of hemodialysis and peritoneal dialysis
patients (abstracted from prospective surveys conducted
specifically for DMMS WAVE 2) were matched and
weighted to allow more appropriate comparisons
between modalities. Baseline and follow-up data used in
the study are shown in Table 1 [see Additional file: 1]. All
results are reported as N (%) or the mean ± the standard
deviation. Patients with ESRD due to HIVAN were deter-
mined from the variable PDIS (primary cause of renal fail-
ure) from the file SAF.PATIENTS and merged with the
DMMS WAVE 2 files using unique patient identifiers.
Causes of renal failure selected as HIVAN were 0429A,
0429Z, 0439Z, or 0449Z (various codes for HIV or AIDS
associated nephropathy), from the variable PDIS in the
file SAF.PATIENTS, Core CD and were coded as 1 in statis-
tical analysis, with all other patients coded as 0. AIDS
associated nephropathy was listed as a diagnosis in the
years studied and therefore that term is still used in the
present study. In addition, a maximum of 15 medications
prescribed to each patient at the study start date (day 60
of dialysis) were recorded. From this list, the use of beta-
blockers (both cardioselective and non-selective), angi-
otensin-converting enzyme (ACE) inhibitors, calcium
channel blockers (subcategorized as dihyropyridine and
non-dihydropyridine), 3-hydroxy-3-methylglutaryl coen-
zyme A (HMG-CoA) reductase inhibitors (statins), and
aspirin was determined. Carvedilol, which has been inde-
pendently associated with improved survival in certain
populations, was approved for use by the FDA in February
1997, and was therefore not assessed. Blood pressureBMC Nephrology 2003, 4 http://www.biomedcentral.com/1471-2369/4/5
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levels, systolic and diastolic, were obtained as the mean of
three readings before and after dialysis, respectively. Of
the study cohort, 2198 (65.1%) of patients with the vari-
able HIV and 2164 (64.1%) with the variable AIDS,
respectively, were either missing, unknown, or coded as
"cannot disclose," and these variables were therefore not
used in analysis.
Survival status was linked to the DMMS Wave 2 data from
the 2000 USRDS Patients Standard Analysis File
(SAF.PATIENTS) via unique patient identifiers assigned
by the USRDS. The date and cause of death listed in a
patient's SAF was obtained from a form submitted to the
USRDS by the patient's nephrologist (form HCFA 2746).
Descriptions of these files are available under the "USRDS
Researcher's Guide" at http://www.usrds.org/
research.htm. Patient survival status was complete
through March 2000. Survival time was defined as the
time from 90 days after the date of the first dialysis session
until the date of death, censored for receipt of renal trans-
plant, loss to followup or the end of the study period. For
comparison, models that did not censor for the date of
receipt of renal transplant were also used.
Statistical analysis
Continuous variables are presented as mean ± standard
deviation unless otherwise specified. Univariate analysis
was performed with Chi-Square testing for categorical var-
iables (Fisher exact test used for violations of Cochran's
assumptions, meaning fewer than 5 cases per cell) and
student's t-test for continuous variables (Mann Whitney
test or logarithmic transformation was used for variables
without a Gaussian distribution, verified by visual inspec-
tion and goodness of fit tests (Chi Square for linear trend).
Variables with borderline significance (p value < 0.1 in
univariate analysis) and those thought likely to have a
clinical relationship with HIVAN were entered into the
multivariate models. Stepwise (forward step likelihood
ratio method) Cox proportional hazards analysis was
used to assess the association between baseline factors
and HIVAN, independent of other factors. This method
used the most computationally intensive method for cal-
culating mean hazard ratios (approximations of relative
risk) entering each variable into the model and removing
those that were no longer significant after adjustment for
all other variables. Log-log plots were inspected to verify
the existence of proportional hazards. Estimated hazard
ratios (HR) along with corresponding 95% confidence
intervals (CI) and p values are reported for all regression
covariates. The association of HIVAN with mortality was
also tested by Cox regression analysis using adjusted haz-
ard ratios (AHR). Hierarchically well-formed models were
used in the assessment of interaction terms. Collinearity
diagnostics were evaluated both from the output of the
statistical procedures and by manual generation of mod-
els including only one of several variables with close rela-
tionships (for example, malnutrition, body mass index
and serum albumin). To assess for possible confounding,
logistic regression was also performed to assess for signif-
icant associations with a history of HIVAN using the same
covariates as for Cox Regression as above. Multiple meth-
ods were used to assess goodness of fit with all variables,
including Nagelkerke r2 (an attempt to quantify the pro-
portion of explained "variation" in the logistic regression
model, although values for r2 in logistic regression are
much lower than for linear regression) and the c-statistic,
which is the receiver operating curve for the cumulative
predicted probability of the logistic regression model (0.5
being equivalent to chance and 1.0 equivalent to 100%
agreement).
Results
A total of 4065 patients were included in the DMMS Wave
2 cohort. Of these, 3621 patients had valid dates for start-
ing dialysis in 1996. From this cohort, 3374 had sufficient
information to calculate follow-up times. Thirty-six of
these patients had ESRD as a result of HIVAN. Mean fol-
low-up was 2.19 ± 1.14 (standard deviation) years. Char-
acteristics of all the patients and patients with HIVAN are
summarized in Table 1 (see Additional file 1). As shown,
in this file factors positively associated with HIV in univar-
iate analysis included male gender, African American race,
younger age, lower body mass index, decreased comorbid-
ity in general, increased rates of malnutrition and smok-
ing, lower blood pressure and cholesterol, higher serum
creatinine, lower serum albumin bicarbonate, and
decreased use of aspirin and calcium channel blockers.
The distribution of serum PTH levels in the study popula-
tion was severely skewed, with a skewness of 2.49 and a
kurtosis of 9.08. We elected to use non-parametric tests of
association (the Mann-Whitney test) and a t-test of loga-
rithmically transformed values of PTH. Although the dif-
ference in serum PTH levels between patients with HIVAN
and patients with other causes of renal disease appeared
large, it was not significant in Mann-Whitney testing (p =
0.34) or t-tests of logarithmically transformed values of
serum PTH (p = 0.64).
Specific antiretroviral agents are also shown in this file.
The most common agents used in HIVAN patients were
zidovudine and lamivudine. Only 22 (61%) of patients
with HIVAN received antiretroviral agents, and only nine
patients (25%) received combination antiretroviral ther-
apy. Five patients received both zidovudine and lamivu-
dine (a combination later called CombivirTM). Other
combinations included one each for zidovudine-zalcitab-
ine, stavudine-saquinavir, stavidine-lamivudine, and
indinavir-lamivudine.BMC Nephrology 2003, 4 http://www.biomedcentral.com/1471-2369/4/5
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Table 1 shows factors independently associated with
HIVAN in logistic regression. Factors included antiretrovi-
ral therapy, male gender, African American race, younger
age, lower serum albumin, higher rates of malnutrition
and smoking, and lower use of calcium channel blockers.
There were no significant differences in ACE use by either
HIV or HIVAN status, either unadjusted or adjusted. There
was no significant interaction between ACE and antiretro-
viral therapy.
Patients with HIVAN had significantly lower survival
compared to patients with other causes of ESRD (Table 2,
Figure 1). Plots of survival by ACE use are shown for
HIVAN patients (Figure 2) and for the entire study cohort
(Figure 3). In Cox Regression analysis adjusted for other
factors known to be associated with mortality, HIVAN was
independently associated with increased risk of mortality,
adjusted hazard ratio, 4.74, 95% CI, 3.12–7.32, p <
0.0001. ACE use was not significantly associated with
mortality in the entire cohort in Cox Regression, and it
was not significant as an interaction term with HIVAN (p
= 0.38, adjusted hazard ratio, 1.64, 95% CI, 0.55–4.87).
In stratified analysis limited to patients with HIVAN, ACE
use was not significantly associated with mortality (p =
0.48, AHR = 1.88, 95% CI, 0.33–10.83). Although the risk
of death of patients with HIVAN and ESRD treated with
single antiretroviral drug was higher than those not taking
antiretroviral agents, patients on multiple antiretroviral
drugs had a lower hazard ratio in adjusted analysis (0.62,
95% CI, 0.10–3.86 by Cox Regression), however this was
not statistically significant (Figure 4). Among patients
with HIVAN, the leading causes of death were AIDS
(50%), missing/unknown (10.7%), and cardiac arrest of
unknown cause (10.7%). Factors independently associ-
ated with survival in HIVAN patients are shown in Table
3. The only factor independently associate with improved
survival was African American race, compared to all other
races.
Discussion
The present study found that only 61% of a national sam-
ple of US dialysis patients with HIVAN received antiretro-
viral therapy, consistent with previous regional reports of
58% use of anti-retroviral agents, [8] suggesting that
underutilization of antiretroviral in dialysis patients with
HIVAN is a national problem. HAART use, which the
present study could not directly measure, is also low in
dialysis patients with HIVAN, at 33% according to a recent
single-center study [14]. We found no beneficial effect of
ACE on survival in HIVAN, also consistent with previous
studies [14]. The survival of HIVAN patients on dialysis in
the preset study is also consistent with previous reports
[5,6]. One-year survival of patients with HIVAN was only
53% compared to 83% for patients with all other causes
of ESRD. This survival is lower than reported recently by
Ahuja et al. [6] in HIV infected patients starting dialysis in
the United States after 1997, likely from the fact that
patients included in the DMMS wave 2 were recruited in
1996. Although data on CD4 counts and viral loads were
unavailable from the database (the importance of which
is illustrated in two reviews.[19,20] HIVAN is generally a
late manifestation of HIV infection. [21] Therefore, use of
antiretroviral therapy would be expected in patients with
HIVAN in the absence of definite contraindications, even
disregarding the previously cited reports of a possible ben-
eficial effect of HAART on the course of HIVAN itself.
However, in the present study only 61% of patients with
HIVAN were receiving antiretroviral therapy and 41% of
these were only on single antiretroviral therapy. Although
not statistically significant, there was a trend towards bet-
ter survival of patients on two antiretroviral drugs. None
of the patients was on more then two antiretroviral drugs.
This underutilization of antiretroviral therapy could be
due hesitancy on the part of the infectious disease special-
ists and nephrologists for using these drugs due to una-
vailability of data on the pharmacokinetics of these drugs
in patients on dialysis. Providers may also be concerned
about the nephrotoxicity of certain antiretroviral agents,
notably indinavir-associated crystal induced renal failure,
[22] and other antiretroviral agents that require dose
Table 2: Logistic Regression of Factors Associated with HIVAN, entire cohort
P value Adjusted odds ratio for HIVAN 95% CI
Age <48 (vs. > = 71)* 0.005 9.35 1.99, 43.48
Serum albumin (per higher quartile) <0.001 0.31 0.15, 0.69
Male (vs. female) 0.001 6.58 2.39, 18.11
African American <0.001 11.03 4.09, 27.78
CCB use (vs. other medications) 0.02 0.23 0.07, 0.75
Malnourished (vs. adequate nutrition) 0.001 4.09 1.56, 10.72
Smoking (vs. non active smoking) 0.02 2.89 1.16, 7.18
HIVAN=Human immunodeficiency virus associated nephropathy. *Other age categories were not statistically significant when compared to age > = 
71 years Nagelkerke r2 was 0.50, c-statistic was 0.97 (95% CI, 0.96, 0.99)BMC Nephrology 2003, 4 http://www.biomedcentral.com/1471-2369/4/5
Page 5 of 7
(page number not for citation purposes)
adjustment in renal failure. [22] Urgent studies are there-
fore needed to understand factors responsible for this
underutilization of HAART in these patients. Similar
underutilization of medications known to be beneficial in
patients with chronic kidney disease has also been
reported for cardiovascular disease. [18,23], suggesting
such practice may not be an isolated phenomenon. How-
ever, the long term tolerability and efficacy of HAART has
not been studied in patients on dialysis.
Although a benefit of ACE use in HIV infected patients has
been reported previously, [9] the benefits of ACE in
retarding progression of renal failure in patients with
HIVAN did not translate into improvement of survival of
these patients on dialysis. This is in agreement with some
Survival, Dialysis Morbidity and Mortality Wave II Cohort  (DMMS II), 1996 only, N = 3374, patients with Human Immu- nodeficiency Virus (HIV) associated nephropathy (HIVAN) vs  patients with other causes of end stage renal disease (ESRD),  p < 0.01 by Log Rank Test Figure 1
Survival, Dialysis Morbidity and Mortality Wave II Cohort 
(DMMS II), 1996 only, N = 3374, patients with Human Immu-
nodeficiency Virus (HIV) associated nephropathy (HIVAN) 
vs. patients with other causes of end stage renal disease 
(ESRD), p < 0.01 by Log Rank Test.
Survival in HIVAN infected patients on chronic dialysis, 1996  DMMS II, by angiotensin converting enzyme inhibitor (ACE)  use Figure 2
Survival in HIVAN infected patients on chronic dialysis, 1996 
DMMS II, by angiotensin converting enzyme inhibitor (ACE) 
use. P = 0.53 by Log Rank Test.
Survival in patients on chronic dialysis, 1996 DMMS II, by  angiotensin converting enzyme inhibitor (ACE) use Figure 3
Survival in patients on chronic dialysis, 1996 DMMS II, by 
angiotensin converting enzyme inhibitor (ACE) use. P = 0.85 
by Log Rank Test.
Survival, Dialysis Morbidity and Mortality Wave II Cohort  (DMMS II), 1996 only, N = 3374, patients with Human Immu- nodeficiency Virus (HIV) associated nephropathy (HIVAN)  who received combination retroviral therapy (COMBO) vs.  all those who did not (NO COMBO), including those who  were treated with single anti-retroviral agents, p = 0.77 by  Log Rank Test Figure 4
Survival, Dialysis Morbidity and Mortality Wave II Cohort 
(DMMS II), 1996 only, N = 3374, patients with Human Immu-
nodeficiency Virus (HIV) associated nephropathy (HIVAN) 
who received combination retroviral therapy (COMBO) vs. 
all those who did not (NO COMBO), including those who 
were treated with single anti-retroviral agents, p = 0.77 by 
Log Rank Test.BMC Nephrology 2003, 4 http://www.biomedcentral.com/1471-2369/4/5
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recommendations that ACE use, to be effective, must start
early in the course of HIVAN. As the number of patients
with HIVAN who were treated with ACE was small in the
present cohort, further prospective studies are required to
validate our initial observation.
In comparison to patients with other causes of ESRD, the
patients with HIVAN included in the DMMS wave 2 study
were younger, the majority were African-Americans and
had lower serum albumin and more severe acidosis. Some
reports have suggested that HIV can infect parathyroid
cells and these patients have low parathyroid hormone
(PTH) and 1,25 dihydroxyvitamin D3 levels. [24] How-
ever, this did not prevent development of secondary
hyperparathyroidism in patients with HIVAN and ESRD.
The mean PTH level of the patients with HIVAN was 225
± 42.6 pcg/L, although lower was not statistically different
from patients with causes of ESRD.
The present study has several limitations: it is observa-
tional and not randomized, therefore, confounding might
persist despite adjustment. It is a random sample of all
hemodialysis patients, not the total population, although
the peritoneal dialysis population is almost fully cap-
tured. Information bias could have arisen due to mistakes
in coding, especially for medications. We did not know
the duration of use of medications prior to the study start.
We were also unable to follow changes in variables over
time. Therefore, we could not follow changes in blood
pressure, laboratory values, or dialysis adequacy. This
most especially applied to possible changes in medication
use and changes in patient dry weight. These same limita-
tions apply to other published studies using this database.
In addition the information on CD4 count and plasma
viral load in patients with HIVAN was not available and
this could be an important uncorrected confounding fac-
tor. We could not assess factors associated with HIV
seropositivity or AIDS due to the high percentage of
patients with missing values for these variables.
In summary, we conclude that patients with HIVAN have
a lower survival compared to patients with ESRD from
other causes. Antiretroviral therapy is underutilized and
the use of ACE does not improve survival of these
patients. Future prospective studies are required to deter-
mine efficacy and tolerability of HAART and ACE inhibi-
tors in patients with HIVAN and ESRD.
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Table 3: 
Percent survival 1-year 2-year 3-year
HIVANA 53 31 28
Patients at risk 19 11 10
Dialysis Patients with other causes of renal failure 83 66 49
Patients at risk 2707 2180 1722
AUnadjusted cumulative percent survival, censored for receipt of renal transplant HIVAN=ESRD due to HIV/AIDS associated nephropathy 
AIDS=acquired immunodeficiency syndrome
Table 4: Cox Regression of Factors Associated with Mortality, DMMS WAVE 2 patients with HIVAN only
One-Year Unadjusted
Survival Factor Present
One-Year Unadjusted
Survival Factor Absent
P Value AHR 95% CI
African American Race* (vs. all other races) 54% 40% 0.05 0.20 0.04, 0.99
Two-Year Unadjusted Survival Two-Year Unadjusted Survival
Antiretroviral therapy (yes/No) 15% 39% 0.21 1.92 0.69, 5.37
Multiple antiretroviral agents (yes/No) 22% 33% 0.60 0.62 0.10, 3.86
ACE inhibitors (vs. nonuse) 13% 29% 0.28 2.26 0.55, 9.31
CCB (vs. nonuse) 42% 25% 0.36 0.56 0.16, 1.96
Male (vs. female) 33% 17% 0.31 0.44 0.09, 2.16
Peritoneal Dialysis (vs. Hemodialysis) 38% 26% 0.47 0.58 0.13, 2.53
N = 36, N in final model = 30 *Because so few patients with HIVAN were not African American, only one-year survival could be compared Only 
factors significant in the final model are shown.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Nephrology 2003, 4 http://www.biomedcentral.com/1471-2369/4/5
Page 7 of 7
(page number not for citation purposes)
Authors' contributions
KCA performed the primary data analysis and collabo-
rated in the writing of the manuscript.
FCT derived the algorithms for the medication variables
and collaborated in the writing of the manuscript.
LYA provided the USRDS CD data files and supervised the
project, and collaborated in the writing of the manuscript.
TSA collaborated in the writing of the manuscript.
Note
The opinions are solely those of the authors and do not
represent an endorsement by the Department of Defense
or the National Institutes of Health. This is a U.S. Govern-
ment work. There are no restrictions on its use
Additional material
References
1. al-Sulaiman M, al-Khader AA, al-Hasani MK and Dhar JM: Impact of
HIV infection on dialysis and renal transplantation Transplant
Proc 1989, 21:1970-1971.
2. Feinfeld DA, Kaplan R, Dressler R and Lynn RI: Survival of human
immunodeficiency virus-infected patients on maintenance
dialysis Clin Nephrol 1989, 32:221-224.
3. Obayomi OO, Dillard MG, Hosten AO and Cruz IA: End-stage
renal disease in patients infected with human immunodefi-
ciency virus: a retrospective review of 38 cases J Natl Med Assoc
1995, 87:762-765.
4. Perinbasekar S, Brod-Miller C, Pal S and Mattana J: Predictors of
survival in HIV-infected patients on hemodialysis Am J Nephrol
1996, 16:280-286.
5. Abbott KC, Hypolite I, Welch PG and Agodoa LY: Human immun-
odeficiency virus/acquired immunodeficiency syndrome-
associated nephropathy at end-stage renal disease in the
United States: patient characteristics and survival in the pre
highly active antiretroviral therapy era J Nephrol 2001, 14:377-
383.
6. Ahuja TS, Grady J and Khan S: Changing trends in the survival of
dialysis patients with human immunodeficiency virus in the
United States J Am Soc Nephrol 2002, 13:1889-1893.
7. Ahuja TS, Borucki M and Grady J: Highly active antiretroviral
therapy improves survival of HIV-infected hemodialysis
patients Am J Kidney Dis 2000, 36:574-580.
8. Szczech LA, Kalayjian R, Rodriguez R, Gupta S, Coladonato J and Win-
ston J: The clinical characteristics and antiretroviral dosing
patterns of HIV-infected patients receiving dialysis Kidney Int
2003, 63:2295-2301.
9. Kimmel PL, Mishkin GJ and Umana WO: Captopril and renal sur-
vival in patients with human immunodeficiency virus
nephropathy Am J Kidney Dis 1996, 28:202-208.
10. Burns GC, Paul SK, Toth IR and Sivak SL: Effect of angiotensin-
converting enzyme inhibition in HIV-associated
nephropathy J Am Soc Nephrol 1997, 8:1140-1146.
11. Efrati S, Zaidenstein R, Dishy V, Beberashvili I, Sharist M, Averbukh Z,
Golik A and Weissgarten J: ACE inhibitors and survival of hemo-
dialysis patients Am J Kidney Dis 2002, 40:1023-9.
12. Laradi A, Mallet A, Beaufils H, Allouache M and Martinez F: HIV-
associated nephropathy: outcome and prognosis factors.
Groupe d' Etudes Nephrologiques d'Ile de France J Am Soc
Nephrol 1998, 9:2327-35.
13. Sheehan MT and Wen SF: Hyperkalemic renal tubular acidosis
induced by trimethoprim/sulfamethoxazole in an AIDS
patient Clin Nephrol 1998, 50:188-93.
14. Rodriguez RA, Mendelson M, O'Hare AM, Hsu LC and Schoenfeld P:
Determinants of Survival among HIV-Infected Chronic Dial-
ysis Patients J Am Soc Nephrol 2003, 14:1307-13.
15. Ross MJ and Klotman PE: Recent Progress in HIV-Associated
Nephropathy J Am Soc Nephrol 2002, 13:2997-3004.
16. Winston JA, Bruggeman LA and Ross MD et al.: Nephropathy and
establishment of a renal reservoir of HIV type I during pri-
mary infection N Engl J Med 2001, 344:1979-1984.
17. Kirschner JT: Resolution of renal failure after initiation of
HAART: 3 cases and a discussion of the literature AIDS Read
2002, 12:103-105.
18. Trespalacios FC, Taylor AJ, Agodoa LY and Abbott KC: Incident
acute coronary syndromes in chronic dialysis patients in the
United States Kidney Int 2002, 62:1799-1805.
19. Weller IV and Williams IG: ABC of AIDS. Antiretroviral drugs
BMJ 322(7299):1410-2. 2001 Jun 9
20. Mindel A and Tenant-Flowers M: ABC of AIDS: Natural history
and management of early HIV infection BMJ 322(7297):1290-
3. 2001 may 26
21. Rao TK: Human immunodeficiency virus infection and renal
failure Infect Dis Clin North Am 2001, 15:833-850.
22. Reilly RF, Tray K and Perazella MA: Indinavir nephropathy revis-
ited: a pattern of insidious renal failure with identifiable risk
factors Am J Kidney Dis 2001, 38:E23.
23. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS
and McClellan MB: Association of renal insufficiency with
treatment and outcomes after myocardial infarction in eld-
erly patients Ann Intern Med 2002, 137:555-562.
24. Haug CJ, Aukrust P, Haug E, Morkid L, Muller F and Froland SS:
Severe deficiency of 1,25-dihydroxyvitamin D3 in human
immunodeficiency virus infection: association with
immunological hyperactivity and only minor changes in cal-
cium homeostasis J Clin Endocr Metab 1998, 83:383-388.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2369/4/5/prepub
Additional file 1
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2369-4-5-S1.doc]